Year: 2020

BERGENBIO CONFIRMS FIRST COVID-19 PATIENT ENROLLED WITH BEMCENTINIB IN ACCORD TRIAL

December 8, 2020

Bergen, Norway, 8 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO PRESENTS UPDATED CLINICAL DATA FROM TWO PHASE II STUDIES OF BEMCENTINIB IN AML AND MDS PATIENTS AT ASH 2020

December 6, 2020

Bergen, Norway, 6 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO TO PRESENT AT UPCOMING HEALTHCARE CONFERENCES IN DECEMBER 2020

December 3, 2020

Bergen, Norway, 3 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTINIB AS A POTENTIAL TREATMENT FOR COVID-19 IN INDIA

November 24, 2020

Bergen, Norway, 24 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO HOSTING VIRTUAL R&D Day TODAY

November 13, 2020

Bergen, Norway, 06 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BERGENBIO PRESENTS PHASE II BEMCENTINIB COMBINATION STUDY IN NSCLC AT annual SITC meeting

November 11, 2020

Bergen, Norway, 11 November 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More